Days to Event356 days
VenueSingapore
Abstract DeadlineFebruary 20, 2027
Early Bird EndsJuly 14, 2026
Register Now
GCGD
Gastroenterology-2027
May 27-28|Singapore

List of Topics

Home » Topics
01 Topics

Every session topic at GCGD 2027.

A complete, searchable index of session topics across 35 scientific sessions. Use this page to plan your attendance or to find the right call for your abstract submission.

01 Track

Inflammatory Bowel Disease

Crohn’s, UC, biologics, JAK inhibitors and treat-to-target.

Track details
  • IL-23 inhibitors: risankizumab and mirikizumab in moderate-to-severe disease
  • Etrasimod (S1P modulator) and upadacitinib (JAK1) positioning
  • STRIDE-II treat-to-target and intestinal ultrasound monitoring
  • Head-to-head trials: SEQUENCE, VEGA combination induction
  • Perianal Crohn’s disease and stem-cell therapy (darvadstrocel)
  • Therapeutic drug monitoring for anti-TNFs and vedolizumab
  • Pouchitis and chronic antibiotic-refractory pouch inflammation
02 Track

Hepatology & Liver Disease

NAFLD/NASH, viral hepatitis, cirrhosis and transplantation.

Track details
  • Resmetirom and the MAESTRO-NASH biopsy endpoints
  • GLP-1 and dual agonists in MASH: ESSENCE, survodutide phase 3
  • HBV functional cure: bepirovirsen siRNA and capsid inhibitors
  • BAVENO VII: non-selective beta-blockers and CARENA data
  • Normothermic and hypothermic machine perfusion in DCD livers
  • HCC surveillance and systemic therapy (atezolizumab/bevacizumab, durvalumab/tremelimumab)
  • Acute-on-chronic liver failure: CLIF-C scoring and transplant timing
03 Track

Endoscopy & Interventional GI

Advanced endoscopy, ERCP, EUS and third-space procedures.

Track details
  • ESD vs EMR for early gastric, esophageal and colorectal neoplasia
  • POEM and EndoFLIP-guided achalasia management
  • Cholangioscopy with electrohydraulic and laser lithotripsy
  • EUS-guided gastroenterostomy and lumen-apposing metal stents
  • Endoscopic sleeve gastroplasty and intragastric balloons
  • GLP-1 receptor agonists and perioperative aspiration (ASA guidance)
  • AI-assisted polyp detection and characterization (CADe/CADx)
04 Track

GI Oncology

Colorectal, gastric, pancreatic and esophageal cancers.

Track details
  • ctDNA-guided adjuvant therapy in colon cancer (DYNAMIC, GALAXY)
  • Neoadjuvant immunotherapy in MMR-deficient rectal and colon cancer
  • HER2 and CLDN18.2 in gastric/GEJ: trastuzumab deruxtecan, zolbetuximab
  • Pancreatic cancer: KRAS G12C/G12D inhibitors and mRNA neoantigen vaccines
  • Barrett’s esophagus surveillance: WATS3D, AI and EET
  • Cholangiocarcinoma: FGFR2 fusions, IDH1 mutations, targeted therapy
  • Hereditary GI cancer syndromes and universal MMR screening
05 Track

Functional GI & Motility

IBS, gastroparesis and neurogastroenterology.

Track details
  • IBS-D: eluxadoline, rifaximin and low-FODMAP evidence
  • IBS-C: linaclotide, plecanatide, tenapanor mechanisms and outcomes
  • Achalasia subtyping: HRM Chicago Classification 4.0 and EndoFLIP
  • Gastroparesis: prucalopride, relamorelin and G-POEM outcomes
  • GERD long-term PPI safety and vonoprazan as PCAB alternative
  • Central neuromodulators in DGBI: TCAs, SNRIs, atypical agents
  • Cyclic vomiting and cannabinoid hyperemesis syndrome
06 Track

Gut Microbiome

FMT, microbiota-based therapeutics and dysbiosis.

Track details
  • Vowst (SER-109) and Rebyota for recurrent C. difficile prevention
  • FMT in ulcerative colitis and pouchitis: donor selection and outcomes
  • Microbiota modulation of immune checkpoint inhibitor response
  • Engineered consortia and defined live biotherapeutic products
  • Shotgun metagenomics standardization and clinical reporting
  • Bile acid–microbiome axis in cholestatic and metabolic disease
  • Helicobacter pylori AMR: vonoprazan-amoxicillin and rifabutin regimens
07 Track

Pediatric Gastroenterology

Pediatric IBD, celiac disease and feeding disorders.

Track details
  • Pediatric IBD: weight-based biologics and small-molecule extrapolation
  • Eosinophilic esophagitis: dupilumab and budesonide oral suspension
  • Very-early-onset IBD: monogenic workup (IL10R, XIAP, CYBB)
  • Pediatric MASLD: lifestyle, vitamin E and emerging pharmacotherapy
  • Intestinal failure and short bowel: teduglutide and autologous reconstruction
  • Avoidant/restrictive food intake disorder (ARFID) and feeding clinics
  • Transition of care from pediatric to adult IBD programs
08 Track

Nutrition & Celiac Disease

Enteral/parenteral nutrition and gluten-related disorders.

Track details
  • ZED1227 (TG2 inhibitor) and latiglutenase in celiac disease
  • Refractory celiac disease and EATL surveillance
  • Anti-IL-15 (AMG 714) and immunomodulators for celiac
  • Home parenteral nutrition and teduglutide in short bowel syndrome
  • Post-bariatric micronutrient deficiencies and surveillance
  • GLP-1/GIP dual agonists: tirzepatide, retatrutide in obesity
  • ESPEN protein and energy targets in critical illness
09 Track

AI in GI

Polyp detection, histology prediction and decision support.

Track details
  • CADe systems: GI Genius, ENDO-AID, CAD EYE ADR outcomes
  • CADx and resect-and-discard for diminutive polyps
  • AI for Barrett’s dysplasia and early esophageal neoplasia
  • Deep learning in capsule endoscopy and small-bowel imaging
  • Automated UCEIS and Mayo endoscopic scoring
  • Histopathology AI: dysplasia, MSI and HER2 prediction
  • Regulatory pathways (FDA SaMD, EU MDR) and post-market surveillance

Have research aligned to one of these topics?

Submit your abstract by February 20, 2027. Oral and poster presentations are welcome across all nine tracks.

Submit Abstract